SABCS New Data Emerges for Liquid Biopsy in Breast Cancer Residual Disease Detection Premium Foundation Medicine's ctDNA assay was able to subclassify patients into higher and lower recurrence risk groups with CTCs providing an additional boost. UK Study Details Liquid Biopsy's Ability to Guide Metastatic Breast Cancer Treatment The researchers used the Guardant360 assay and droplet digital PCR to identify genetic mutations in circulating tumor DNA that had been shed into the patients' bloodstream. Immunotherapy Regimens Yield Contrasting Results in Early Triple Negative Breast Cancer Premium In two trials in the neoadjuvant setting reported at SABCS, one showed improved rates of pathologic complete response with added immunotherapy, and the other showed no difference. SABCS 2018 Features Molecular Diagnostics Research At the conference, researchers presented data from a number of studies using molecular diagnostic tools to better characterize breast cancer recurrence and treatment outcomes. Novartis Drug Shows Promise in PIK3CA Mutated Breast Cancer, Potential Utility of ctDNA Testing Premium Qiagen and Foundation Medicine will develop tissue- and plasma-based companion tests to identify best responders to the PI3K inhibitor alpelisib Dec 6, 2018 Myriad Genetics Describes Advancement of Hispanic-Specific Breast Cancer Polygenic Risk Score Premium Dec 6, 2018 Triple-Negative Breast Cancer Patient Subset Sees Benefit From Drug; Genomic Analysis Underway Premium Dec 5, 2018 Genentech Data Shows Breast Cancer Patient Subgroups May Benefit from Its Drugs Premium Dec 8, 2017 Pfizer PARP Inhibitor Delays Progression Over Chemotherapy in BRCA-Mutated Advanced Breast Cancer Premium Dec 7, 2017 Myriad Genetics Breast Cancer Risk SNP Score Improves Upon Traditional Measures, Study Shows Premium Dec 14, 2016 Breast Cancer Survival High for Oncotype DX Low-Risk Patients With Grade 3 Tumors Premium Dec 13, 2016 Provista Presents SABCS Studies on Performance, Reproducibility of Videssa Breast Test Premium Dec 13, 2016 Breast Cancer Prognostic Test Comparison Considers Strengths, Weaknesses of Different Signatures Premium Dec 9, 2016 Novartis PI3K Inhibitor Effective in Breast Cancer Subset; Psych Toxicities Dampen Enthusiasm Premium Dec 8, 2016 Mayo, Ambry Genetics Analyze Large Cohort to Refine Breast Cancer Risk Genes on NGS Panels Premium Dec 8, 2016 AbbVie Pursues Phase III Veliparib Study in BRCA Mutated Breast Cancer After Phase II Survival Trend Premium Dec 8, 2016 Molecular Changes in Metastatic Breast Cancer May Hold Key to Treatment, SABCS Presentations Show Dec 11, 2015 Study Suggests EndoPredict Clinical Score Outperforms Oncotype DX for Assessing Late Recurrence Premium Dec 9, 2015 Readying HRD Test for Early-Access Launch, Myriad Reports Data to Strengthen Predictive Claims Premium Dec 12, 2014 Researchers Present Data from Second Validation Study of Genomic Health Oncotype DX DCIS Test Dec 12, 2014 HRD Test, BRACAnalysis Predict Platinum-based Treatment Benefit in Early-Stage, Advanced TNBC Premium Dec 11, 2014 Phase II Study Shows ER/PR Status, Not PIK3CA Mutations, May ID Responders to PI3K Inhibitor Premium Dec 10, 2014 Researchers Report Early Data Exploring Immune-related Biomarkers in Breast Cancer Therapy Response Premium Dec 18, 2013 As Molecular Understanding of HER2-Positive Breast Cancer Advances, New Treatment Strategies Emerge Premium Dec 18, 2013 I-SPY2 Adaptive Trial Predicts Late-Stage Success for AbbVie's PARP Inhibitor Veliparib in TNBC Premium Load More Breaking News In Brief This Week: Illumina, Personalis, Proteomedix, and More Ancient DNA Details Population Dynamics Within Andean Tiwanaku Civilization Genomic Data Spanning 2K Years Gives Glimpse of Etruscan Origins, Population Changes People in the News: New Appointments at Hologic, Akoya Biosciences, Caris Life Sciences, More At NSGC, Genetic Counselors Address Race-Based Medicine, Ways to Change New Products Posted to GenomeWeb: Becton Dickinson, Cosmos-ID, OncoDNA, More The Scan US Booster Eligibility Decision The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions. Arizona Bill Before Judge The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction. Additional Genes Wales is rolling out new genetic testing service for cancer patients, according to BBC News. Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.